TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35189420

Group type: EXPERIMENTAL
Intervention: Case-tailored 3D-printing models
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no case-tailored model)
Number of subjects: 36
Study: 32640112

Group type: EXPERIMENTAL
Intervention: Surgical drainage with combined strategies
Number of subjects: 169

Group type: COMPARATOR
Intervention: Sphincter-sparing surgeries or seton removal
Number of subjects: 169

Group type: COMPARATOR
Intervention: Fistulotomy
Number of subjects: 169

Group type: COMPARATOR
Intervention: Immunosuppressants
Number of subjects: 169

Group type: COMPARATOR
Intervention: Anterior fistula
Number of subjects: 169

Group type: COMPARATOR
Intervention: Supralevator extension
Number of subjects: 169
Study: 34673535

Group type: EXPERIMENTAL
Intervention: Mobile health intervention using the SaltSwap app with individualized advice from a health care professional
Number of subjects: 47

Group type: COMPARATOR
Intervention: Advice leaflet (control)
Number of subjects: 47
Study: 32544572

Group type: EXPERIMENTAL
Intervention: Yoga practice (90-min classes, 2 times per week for 10 weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Yoga practice
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study: 35584600

Group type: EXPERIMENTAL
Intervention: Hypnosis during bronchoscopy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard bronchoscopy
Number of subjects: 60
Study: 34814074

Group type: EXPERIMENTAL
Intervention: Active learning methods (role-play simulations)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Passive learning methods (lecture)
Number of subjects: 94
Study: 34791350

Group type: EXPERIMENTAL
Intervention: 2 fractional doses of IPV (fIPV-0.1mL, intradermal) at age 6 and 14 weeks
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: 2 fractional doses of IPV (fIPV-0.1mL, intradermal) at age 10 and 14 weeks
Number of subjects: 799

Group type: COMPARATOR
Intervention: 1 full dose of IPV (0.5mL, intramuscular) at age 14 weeks
Number of subjects: 799
Study: 32744906

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 1682

Group type: EXPERIMENTAL
Intervention: Oral steroids with acupuncture
Number of subjects: 1682

Group type: COMPARATOR
Intervention: OA nonacupuncture cohort
Number of subjects: 1682

Group type: COMPARATOR
Intervention: Non-OA cohort
Number of subjects: 1682
Study: 32564093

Group type: EXPERIMENTAL
Intervention: 300 mg oral micronized progesterone at bedtime
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Observational data
Number of subjects: 60
Study: 35202010

Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 33277768

Group type: EXPERIMENTAL
Intervention: Aetiological testing using Xpert® CT/NG and Xpert® TV assays
Number of subjects: 841

Group type: COMPARATOR
Intervention: Syndromic management
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Aetiological testing
Number of subjects: 841
Study: 35033346

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation, 60 g of product containing 30 g of FO daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Canola oil (CO) supplementation, 30 mL daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 30
Study: 34925649

Group type: EXPERIMENTAL
Intervention: Ramipril (1.25 mg/d)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg/d)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (traditional therapy only)
Number of subjects: 64
Study: 34565193

Group type: EXPERIMENTAL
Intervention: CancerHelp-Talking Touchscreen (CancerHelp-TT)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control
Number of subjects: 129
Study: 32192465

Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard wound closure
Number of subjects: 30
Study: 35960047

Group type: EXPERIMENTAL
Intervention: QFPD-LHQW
Number of subjects: 318

Group type: COMPARATOR
Intervention: QFPD
Number of subjects: 318

Group type: COMPARATOR
Intervention: LHQW
Number of subjects: 318
Study: 33432439

Group type: EXPERIMENTAL
Intervention: Curcumin for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 30
Study: 33323306

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (2 mA current, 20 minutes per session, repeated once daily for 5 consecutive days)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham stimulation (30 seconds stimulation, 20 minutes no current)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups received acetaminophen
Number of subjects: 54
Study: 32074356

Group type: EXPERIMENTAL
Intervention: 2% pilocarpine ophthalmic solution (two drops)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2% pilocarpine ophthalmic solution (three drops)
Number of subjects: 0
Study: 32296971

Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure (LAAC)
Number of subjects: 623
Study: 32095922

Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations (MOPs) applied to the maxillary molar region (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Contralateral side of the experimental group (n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations (MOPs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group and experimental group (contralateral side)
Number of subjects: 20
Study: 35994437

Group type: EXPERIMENTAL
Intervention: Brief psychotherapy
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Short-term psychotherapy
Number of subjects: 236
Study: 32404782

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted quadrivalent influenza vaccine (aIIV4)
Number of subjects: 10644

Group type: COMPARATOR
Intervention: Nonadjuvanted comparator influenza vaccine
Number of subjects: 10644
Study: 33536049

Group type: COMPARATOR
Intervention: ctDNA methylation markers in early detection of CRC (training set)
Number of subjects: 742

Group type: COMPARATOR
Intervention: ctDNA methylation markers in early detection of CRC (test set)
Number of subjects: 742

Group type: COMPARATOR
Intervention: ctDNA methylation markers for stage I CRC
Number of subjects: 742

Group type: COMPARATOR
Intervention: ctDNA methylation markers for stage II CRC
Number of subjects: 742

Group type: COMPARATOR
Intervention: ctDNA methylation markers for stage III CRC
Number of subjects: 742

Group type: COMPARATOR
Intervention: ctDNA methylation markers for stage IV CRC
Number of subjects: 742

Group type: COMPARATOR
Intervention: ctDNA methylation markers for stage I-III CRC (training set)
Number of subjects: 742

Group type: COMPARATOR
Intervention: ctDNA methylation markers for stage I-III CRC (test set)
Number of subjects: 742

Group type: COMPARATOR
Intervention: ctDNA methylation markers compared to methylated SEPT9 model
Number of subjects: 742
Study: 32819348

Group type: EXPERIMENTAL
Intervention: Shelter group (temporary housing residents)
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Community residents (non-disaster areas)
Number of subjects: 1089
Study: 35170247

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate mouthwash
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Zinc chloride mouthwash
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 144
Study: 34387828

Group type: EXPERIMENTAL
Intervention: Herbal application for acupoints (HAA) group
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo application for acupoints (PAA) group
Number of subjects: 121
Study: 35717169

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 2395

Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 2395
Study: 33831504

Group type: EXPERIMENTAL
Intervention: Silicone-based resilient denture liner (RD group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional denture base (CD group)
Number of subjects: 0
Study: 33820576

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) 1 capsule containing 1×10^10 cells twice daily (n = 44)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (n = 44)
Number of subjects: 88
Study: 32196717

Group type: EXPERIMENTAL
Intervention: Varicocelectomy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (N=45)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Preoperative MPV
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Total testosterone
Number of subjects: 64
Study: 36195995

Group type: EXPERIMENTAL
Intervention: Normal saline hydration
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 65
Study: 33481771

Group type: EXPERIMENTAL
Intervention: 5-hydroxyindole (5-HI) administered orally in rats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-hydroxyindole (5-HI) stimulation in a cell line model of intestinal enterochromaffin cells
Number of subjects: 0
Study: 32544120

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study: 35821447

Group type: EXPERIMENTAL
Intervention: Motor-control with biofeedback group (N = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Motor-control group (N = 12)
Number of subjects: 24
Study: 33092819

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT) with cisplatin/paclitaxel q21 followed by cold‐knife conization (CKC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 25
Study: 34081314

Group type: EXPERIMENTAL
Intervention: Multi-component intervention (reverse Trendelenburg position, dysphagia screening, oral care, vaccinations)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Multi-component intervention
Number of subjects: 123

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 123
Study: 32898006

Group type: EXPERIMENTAL
Intervention: Systemic anticoagulation (SAC) therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: No systemic anticoagulation (historic cohort)
Number of subjects: 84
Study: 616860962

Group type: EXPERIMENTAL
Intervention: 12.5mg of apo‐carvedilol
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 25mg of apo‐carvedilol
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 35809772

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-fat diet (n = 30)
Number of subjects: 60
Study: 34363864

Group type: EXPERIMENTAL
Intervention: Quarterly professional-mode flash glucose monitoring (sensor worn for 14 days; data discussed at clinic visit)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Quarterly professional-mode flash glucose monitoring
Number of subjects: 299
Study: 32445295

Group type: EXPERIMENTAL
Intervention: Interactive audio-tactile map
Number of subjects: 14

Group type: COMPARATOR
Intervention: Verbally annotated tactile map (Control)
Number of subjects: 14
Study: 35565177

Group type: EXPERIMENTAL
Intervention: New occupational health program implementation
Number of subjects: 32
Study: 34517272

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 0
Study: 35478086

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention for 30 days
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Music intervention for 30 days
Number of subjects: 623

Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 623
Study: 33506031

Group type: EXPERIMENTAL
Intervention: Focused Shockwave Therapy (F‐SWT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Radial Shockwave Therapy (R‐SWT)
Number of subjects: 46
Study: 34881965

Group type: EXPERIMENTAL
Intervention: Cell phone condition
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Paper condition
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 57
Study: 32636360

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 35581452

Group type: EXPERIMENTAL
Intervention: Hybrid arm (digital health intervention + CHW support)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual-care arm (wireless glucometer if needed)
Number of subjects: 150
Study: 32894382

Group type: EXPERIMENTAL
Intervention: Pathways (with a mutual gaze component)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Services-as-usual (SAU)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Communication
Number of subjects: 78
Study: 32402558

Group type: EXPERIMENTAL
Intervention: SS with breast milk (SSB)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: SS with sensory stimulation (SSS)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Oral sucrose alone (S24%)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: SS with sucrose (SSS)
Number of subjects: 108
Study: 34988638

Group type: EXPERIMENTAL
Intervention: Participants who chose to lie during the interview
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants who chose to tell the truth during the interview
Number of subjects: 0
Study: 33851349

Group type: EXPERIMENTAL
Intervention: Bosutinib
Number of subjects: 33

Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 33
Study: 32328782

Group type: EXPERIMENTAL
Intervention: Lobectomy (LT) plus lymph node dissection (LND)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Total thyroidectomy (TT) plus lymph node dissection (LND)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 129
Study: 35701060

Group type: EXPERIMENTAL
Intervention: Musculoskeletal health package (MHP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care (observation)
Number of subjects: 40
Study: 32526534

Group type: COMPARATOR
Intervention: Standard of Care Plus (SCP)
Number of subjects: 1890

Group type: EXPERIMENTAL
Intervention: Collaborative Care/Stepped Care (CC/SC)
Number of subjects: 1890
Study: 34307681

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercises plus Manual Therapy (PRE plus MT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Motor Control Exercises (MCE)
Number of subjects: 80
Study: 32121011

Group type: EXPERIMENTAL
Intervention: Almond supplementation
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 35197068

Group type: EXPERIMENTAL
Intervention: Web-based health education regarding HPV and HPV vaccines for seven days
Number of subjects: 946

Group type: COMPARATOR
Intervention: Non-HPV-related materials (control group)
Number of subjects: 946
Study: 33226075

Group type: EXPERIMENTAL
Intervention: Housing subsidy (MTO voucher treatment)
Number of subjects: 2829

Group type: EXPERIMENTAL
Intervention: Average post-random-assignment COI
Number of subjects: 2829
Study: 32281249

Group type: EXPERIMENTAL
Intervention: Saugella Hydraserum (SIS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lactacyd Feminine Hygiene (LTC)
Number of subjects: 40
Study: 34149690

Group type: EXPERIMENTAL
Intervention: ART initiated during primary HIV infection (PHI) for up to three years
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: HIV-specific cells epigenetic profiling
Number of subjects: 66

Group type: COMPARATOR
Intervention: HIV-uninfected controls
Number of subjects: 66
Study: 33123802

Group type: EXPERIMENTAL
Intervention: DNX HBr hemihydrate tablet formulations in fed state (high fat)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DNX HBr monohydrate formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (fasted state)
Number of subjects: 0
Study: 36195692

Group type: EXPERIMENTAL
Intervention: Technical Decision Support Tool (DST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined Technical and Non-Technical DST
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-Technical DST
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All DSTs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Memory alone
Number of subjects: 0
Study: 33609343

Group type: EXPERIMENTAL
Intervention: Progressive Physical Therapy (PPT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Maintenance Physical Therapy (MPT)
Number of subjects: 35
Study: 32910735

Group type: EXPERIMENTAL
Intervention: Experimental sEMG patch
Number of subjects: 40
Study: 36048440

Group type: EXPERIMENTAL
Intervention: Parent management training program including time-out; 10 sessions, social learning-based.
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control condition (waiting list).
Number of subjects: 205
Study: 33662017

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) plus meibomian gland expression (MGX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intense pulsed light (IPL) alone
Number of subjects: 60
Study: 33440441

Group type: EXPERIMENTAL
Intervention: Transpancreatic biliary sphincterotomy (TPBS)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Double guidewire (DGW)
Number of subjects: 203
Study: 35270295

Group type: EXPERIMENTAL
Intervention: Long HIIE (2 min at 100% vVO2peak + 2 min of passive rest)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Short HIIE (30 s at 100% vVO2peak + 30 s of passive rest)
Number of subjects: 44

Group type: COMPARATOR
Intervention: MICE (14 min at 70% vVO2peak)
Number of subjects: 44
Study: 35486228

Group type: EXPERIMENTAL
Intervention: Capecitabine (group 1)
Number of subjects: 63

Group type: COMPARATOR
Intervention: 5‐Fu and leucovorin (group 2)
Number of subjects: 63
Study: 33845988

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid-enriched transfer medium (EmbryoGlue, 0.5 mg/mL)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Standard transfer medium (supplemented G-2, 0.125 mg/mL)
Number of subjects: 550
Study: 35589874

Group type: EXPERIMENTAL
Intervention: CLAPS (closed-loop automated blood pressure control system)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual control
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CLAPS
Number of subjects: 40

Group type: COMPARATOR
Intervention: CLAPS and Manual
Number of subjects: 40
Study: 33789642

Group type: EXPERIMENTAL
Intervention: Immediate telemedicine linkage to the provider and transportation to pick up induction prescription or attend intake appointment.
Number of subjects: 273

Group type: COMPARATOR
Intervention: Standard referral to treatment.
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Immediate telemedicine linkage to the provider.
Number of subjects: 273
Study: 35073909

Group type: EXPERIMENTAL
Intervention: sQ-HPF questionnaire
Number of subjects: 4400
Study: 35996823

Group type: EXPERIMENTAL
Intervention: Caring Contacts (3 communications via email or mail on days 4, 21, and 56 post-discharge)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control communication (3 communications via email or mail on days 4, 21, and 56 post-discharge)
Number of subjects: 100
Study: 33478976

Group type: EXPERIMENTAL
Intervention: Short regimen (40 mg/m2 on alternate days for 2 weeks)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard regimen (40 mg/m2 on alternate days for 4 weeks)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Short regimen
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Short regimen and Standard regimen
Number of subjects: 117
Study: 33283533

Group type: EXPERIMENTAL
Intervention: Perioperative breathing training
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (standard perioperative care)
Number of subjects: 240
Study: 34469484

Group type: EXPERIMENTAL
Intervention: Blended learning
Number of subjects: 241

Group type: COMPARATOR
Intervention: Didactic teaching
Number of subjects: 241

Group type: COMPARATOR
Intervention: Web-based e-learning
Number of subjects: 241
Study: 36343085

Group type: EXPERIMENTAL
Intervention: Healbot T with pelvic off mode (pelvic off group; n = 11)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Healbot T with pelvic control mode (pelvic on group; n = 12)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Healbot T with constraint-induced movement therapy (CIMT) mode (CIMT group; n = 10)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional physiotherapy (control group; n = 10)
Number of subjects: 47
Study: 33156725

Group type: EXPERIMENTAL
Intervention: Consultant-led sessions on a thoracoscopic simulator
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Self-directed learning sessions on a thoracoscopic simulator
Number of subjects: 32

Group type: COMPARATOR
Intervention: Self-directed 'virtual training' on the 'SimuSurg' application
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 32
Study: 35119520

Group type: EXPERIMENTAL
Intervention: Fitbit Flex™ and daily text messages for 12 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study: 33885718

Group type: EXPERIMENTAL
Intervention: Carboplatin plus Paclitaxel every 3 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Single-agent Carboplatin every 3 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Weekly Carboplatin plus Paclitaxel
Number of subjects: 120
Study: 33877855

Group type: EXPERIMENTAL
Intervention: SLNB-navigated ND
Number of subjects: 271

Group type: COMPARATOR
Intervention: Elective neck dissection (ND)
Number of subjects: 271
Study: 33740213

Group type: EXPERIMENTAL
Intervention: Epic Allies mobile app intervention
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 146
Study: 32355108

Group type: EXPERIMENTAL
Intervention: Extragenital screening at both sites (rectal and pharyngeal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extragenital screening only at the rectal site
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extragenital screening only at the pharyngeal site
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing only rectal screening
Number of subjects: 0
Study: 35649245

Group type: EXPERIMENTAL
Intervention: SAR443060 (DNL747)
Number of subjects: 0
Study: 33682378

Group type: EXPERIMENTAL
Intervention: Ixekizumab (continued treatment every 2 weeks)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo (withdrawal of ixekizumab treatment every 2 weeks)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Re-treatment with ixekizumab after relapse
Number of subjects: 158